Scholarlink

<p>The optimal prognostication model for outcome following allogeneic hematopoietic stem cell transplantation (allo-HSCT) for acute myeloid leukemia (AML) remains undefined. To establish a prognostic scoring system, 466 consecutive AML patients undergoing allo-HSCT from 2014 to 2023 were analyzed as a training cohort. Six donor, leukemia and recipient related factors were identified as prognostically significant and assigned weighted scores, respectively 1 point each for donor cytomegalovirus seropositivity, Hemopoietic Cell Transplantation-specific Comorbidity Index ≥ 2, secondary AML, not in first complete remission, and low-intensity induction therapy; 3 points for inv(3)/t(3;3)(q21;q26) or <i>KMT2A</i> rearrangement; 4 points for − 5/del(5q) or <i>TP53</i> mutation; 0 point for <i>CEBPA</i> bZIP in-frame mutation or core-binding factor AML; and 1 point for all other genetic risk groups. Scores were grouped into four risk categories: favorable (0–1), intermediate (2–3), poor (4–5), and very poor (≥ 6); constituting the HATS prognostication model. The corresponding 2-year overall survivals of favorable, intermediate, poor and very poor risk groups were 92%, 78%, 50%, and 7.4% (log-rank <i>P</i> &lt; 0.001). An external validation cohort comprising 395 patients was similarly analyzed. With concordance statistics, HATS outperformed all six existing prognostication models. In conclusion, HATS represents a novel prognostication model devised for AML patients undergoing allo-HSCT.</p><p>Clinicaltrials.gov identifier: NCT06702111.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A novel prognostic scoring system HATS for acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月9日

查看全文
  • Garret M K Leung,
  • Yishan Ye,
  • Yi Luo,
  • Jimin Shi,
  • Yanmin Zhao,
  • Joycelyn P.Y. Sim,
  • Yok-Lam Kwong,
  • Huang He,
  • Harinder Gill

摘要

The optimal prognostication model for outcome following allogeneic hematopoietic stem cell transplantation (allo-HSCT) for acute myeloid leukemia (AML) remains undefined. To establish a prognostic scoring system, 466 consecutive AML patients undergoing allo-HSCT from 2014 to 2023 were analyzed as a training cohort. Six donor, leukemia and recipient related factors were identified as prognostically significant and assigned weighted scores, respectively 1 point each for donor cytomegalovirus seropositivity, Hemopoietic Cell Transplantation-specific Comorbidity Index ≥ 2, secondary AML, not in first complete remission, and low-intensity induction therapy; 3 points for inv(3)/t(3;3)(q21;q26) or KMT2A rearrangement; 4 points for − 5/del(5q) or TP53 mutation; 0 point for CEBPA bZIP in-frame mutation or core-binding factor AML; and 1 point for all other genetic risk groups. Scores were grouped into four risk categories: favorable (0–1), intermediate (2–3), poor (4–5), and very poor (≥ 6); constituting the HATS prognostication model. The corresponding 2-year overall survivals of favorable, intermediate, poor and very poor risk groups were 92%, 78%, 50%, and 7.4% (log-rank P < 0.001). An external validation cohort comprising 395 patients was similarly analyzed. With concordance statistics, HATS outperformed all six existing prognostication models. In conclusion, HATS represents a novel prognostication model devised for AML patients undergoing allo-HSCT.

Clinicaltrials.gov identifier: NCT06702111.